机构：[1]School of Chemistry and Chemical Engineering, South China University of Technology, 510640 Guangzhou, China.[2]Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, 510515 Guangzhou, China.[3]NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, 510515 Guangzhou, China.[4]Cancer Center, MD TCM-integrated Hospital, Southern Medical University, 510515 Guangzhou, China.
Magnetic resonance imaging (MRI) is an important tool in the diagnosis of many cancers. However, clinical gadolinium (Gd)-based MRI contrast agents have limitations, such as large doses and potential side effects. To address these issues, we developed a hydrogen-bonded organic framework-based MRI contrast agent (PFC-73-Mn). Due to the hydrogen-bonded interaction of water molecules and the restricted rotation of manganese ions, PFC-73-Mn exhibits high longitudinal relaxation r1 (5.03 mM-1 s-1) under a 3.0 T clinical MRI scanner. A smaller intravenous dose (8 μmol of Mn/kg) of PFC-73-Mn can provide strong contrast and accurate diagnosis in multiple kinds of cancers, including breast tumor and ultrasmall orthotopic glioma. PFC-73-Mn represents a prospective new approach in tumor imaging, especially in early-stage cancer.
基金：
Natural Science Foundation
of Guangdong Province (2022A1515010482 and
2022A1515010373), Science and Technology Projects in
Maoming (2022S021).
材料科学